Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer
- Conditions
- Breast Cancer
- Registration Number
- NCT01669265
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Brief Summary
This is a retrospective, multicentric cohort study of patient cases with cT1-3, N0 early breast cancer, who previously had intraoperative sentinel lymph node (SLN) evaluation by one-step nucleic acid amplification (OSNA) assay with a complete axillary dissection.
The aim of the present study is to assess the intraoperative positive SLN total tumor load (TTL) obtained from the OSNA assay and to determine whether this TTL predicts non-SLN metastasis in patients with clinically node-negative early-stage breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 701
-
Pathologically confirmed invasive breast carcinoma
-
Stage T1-3,N0 evaluated by physical exam or imaging according to AJCC v.7 and best clinical local practices
-
Intraoperative evaluation of sentinel lymph node (SLN) by OSNA
-
Complete dissection of axillary lymph nodes after the evaluation of the SLNs by OSNA
-
Pathology report of the tumor and dissected lymph nodes that includes the following information:
- primary tumor size (mm), tumor grade (Scarff-Bloom Richardson), estrogen receptor status
- progesterone receptor status
- HER2 status (ASCO/CAP guidelines)
- Ki67 index
- presence/absence of lymphovascular invasion
- total number of sentinel and non-sentinel lymph nodes dissected during surgery
- total number of positive and negative sentinel and non-sentinel lymph nodes, *size of the metastasis in both sentinel and non-sentinel lymph nodes
- total tumoral load in each sentinel lymph node, expressed as number of CK19 mRNA copies per microliter.
- Patients who underwent neoadjuvant chemotherapy
- CK19-negative breast tumor
- ALND with <10 lymph nodes
- In situ carcinoma only
- Metastatic breast cancer at time of diagnosis
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Estimate the negative predictive value of the technique OSNA. At time of surgery Estimate the negative predictive value of the technique OSNA for the cutoff point that maximizes (tentatively, 10,000 to 15,000 copies / uL) of axillary lymph node involvement in breast cancer early N0.
- Secondary Outcome Measures
Name Time Method ROC curve that describes the assay At time of surgery ROC curve (Receiver Operating Characteristic) from the true and false positives and negatives of OSNA test for different cutoffs
Sensitivity of the assay At time of surgery Probability that OSNA in sentinel lymph nodes (SLN) is positive given that there is involvement of non-sentinel lymph nodes (NSLN)
Specificity of the assay At time of surgery Probability that OSNA in SLN is negative because there is no involvement of NSLN
Likelihood ratio for the cutoff of 10,000-15,000 copies/uL At time of surgery Likelihood ratio of positive and negative results
Positive predictive value at the cutoff of 10.000-15.000 copies/μL. At time of surgery
Trial Locations
- Locations (9)
Hospital Universitario de Bellvitge
🇪🇸Barcelona, Spain
Vall d´Hebron University Hospital
🇪🇸Barcelona, Spain
Hospital Clínico Universitario de Santiago de Compostela
🇪🇸La Coruña, Spain
Hospital Universitario de Gran Canaria Doctor Negrin
🇪🇸Las Palmas, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitario Arnau de Vilanova
🇪🇸Lleida, Spain
Instituto Valenciano de Oncología
🇪🇸Valencia, Spain
Hospital Universitario de Salamanca
🇪🇸Salamanca, Spain
Hospital Universitario Virgen Del Rocio
🇪🇸Seville, Spain